Literature DB >> 12848808

Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety.

Mete Alpaslan1, Ersel Onrat, Murat Samli, Cetin Dincel.   

Abstract

BACKGROUND: Sildenafil is an effective and widely used therapeutic agent for erectile dysfunction. Deaths have been reported due to sildenafil use and most of them are attributed to concurrent use of nitrates. However, the effects of sildenafil on QT intervals, QT dispersion, and the possible risk of ventricular arrhythmia have not been studied before. Our aim in this study was to evaluate the effect of sildenafil citrate on QT intervals and QT dispersion.
METHODS: Thirty-six patients with erectile dysfunction were included in this study. Twenty-one patients had coronary artery disease whereas 12 of them also had accompanying diabetes mellitus. Standard 12-lead electrocardiograms (ECG) were recorded three times: before, and at the first and fourth hours of 50 mg sildenafil citrate ingestion. All QT parameters were corrected for heart rate.
RESULTS: Mean age of the patients was 54 +/- 12 years. The mean heart rate did not differ significantly between the three ECG examinations. The corrected and uncorrected maximum and minimum QT intervals were not significantly different between the three ECG examinations. The QT dispersion and corrected QT dispersion before and 1 hour and 4 hours after sildenafil ingestion were 31 +/- 9 ms, 36 +/- 10 ms; 32 +/- 11 ms, 37 +/- 14 ms; 27 +/- 8 ms, 32 +/- 9 ms, respectively (P > 0.05).
CONCLUSIONS: Sildenafil does not prolong QT intervals or increase QT dispersion in patients with erectile dysfunction. Our results suggest that the risk of ventricular arrhythmia does not increase with ingestion of 50 mg sildenafil.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848808      PMCID: PMC6932612          DOI: 10.1046/j.1542-474x.2003.08103.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  23 in total

1.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

2.  Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.

Authors:  R B Moreland; I Goldstein; A Traish
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

3.  Hypertension as a Risk for Erectile Dysfunction: Implications for Sildenafil Use.

Authors:  Robert A. Kloner
Journal:  J Clin Hypertens (Greenwich)       Date:  2000-01       Impact factor: 3.738

4.  QTc interval prolongation associated with citalopram overdose: a case report and literature review.

Authors:  G Catalano; M C Catalano; M A Epstein; P E Tsambiras
Journal:  Clin Neuropharmacol       Date:  2001 May-Jun       Impact factor: 1.592

5.  Prolongation of the QT interval related to cisapride-diltiazem interaction.

Authors:  A R Thomas; L N Chan; J L Bauman; C O Olopade
Journal:  Pharmacotherapy       Date:  1998 Mar-Apr       Impact factor: 4.705

6.  Usefulness of QT dispersion immediately after exercise as an indicator of coronary stenosis independent of gender or exercise-induced ST-segment depression.

Authors:  Y Koide; M Yotsukura; H Yoshino; K Ishikawa
Journal:  Am J Cardiol       Date:  2000-12-15       Impact factor: 2.778

7.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

Review 8.  Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee.

Authors:  M D Cheitlin; A M Hutter; R G Brindis; P Ganz; S Kaul; R O Russell; R M Zusman
Journal:  Circulation       Date:  1999 Jan 5-12       Impact factor: 29.690

9.  QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.

Authors:  C P Day; J M McComb; R W Campbell
Journal:  Br Heart J       Date:  1990-06

10.  Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias.

Authors:  R G Tieleman; H J Crijns; A C Wiesfeld; J Posma; H P Hamer; K I Lie
Journal:  Br Heart J       Date:  1995-01
View more
  3 in total

Review 1.  Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety.

Authors:  Sumon Roy; Robert A Kloner; Fadi N Salloum; Ion S Jovin
Journal:  Cardiovasc Drugs Ther       Date:  2021-10-15       Impact factor: 3.947

2.  Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis.

Authors:  Dayimi Kaya; Cem Guler; Ali Metin Esen; Irfan Barutcu; Cetin Dincel
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-07       Impact factor: 1.468

Review 3.  The Challenges of Predicting Drug-Induced QTc Prolongation in Humans.

Authors:  Jean-Pierre Valentin; Peter Hoffmann; Catherine Ortemann-Renon; John Koerner; Jennifer Pierson; Gary Gintant; James Willard; Christine Garnett; Matthew Skinner; Hugo M Vargas; Todd Wisialowski; Michael K Pugsley
Journal:  Toxicol Sci       Date:  2022-04-26       Impact factor: 4.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.